title: Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.
abstract: The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
authors.affiliation: INSERM U563, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France.
authors.forename: Aude-Hélène
authors.initials: AH
authors.lastname: Capietto
authors.forename: Samarh
authors.initials: S
authors.lastname: Keirallah
authors.forename: Emilie
authors.initials: E
authors.lastname: Gross
authors.forename: Nicolas
authors.initials: N
authors.lastname: Dauguet
authors.forename: Emilie
authors.initials: E
authors.lastname: Laprévotte
authors.forename: Christine
authors.initials: C
authors.lastname: Jean
authors.forename: Julie
authors.initials: J
authors.lastname: Gertner-Dardenne
authors.forename: Christine
authors.initials: C
authors.lastname: Bezombes
authors.forename: Anne
authors.initials: A
authors.lastname: Quillet-Mary
authors.forename: Mary
authors.initials: M
authors.lastname: Poupot
authors.forename: Loic
authors.initials: L
authors.lastname: Ysebaert
authors.forename: Guy
authors.initials: G
authors.lastname: Laurent
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Fournié
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D008954:Models, Biological; D008958:Models, Molecular; D011993:Recombinant Fusion Proteins
chemical_list: D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins